Mark Chambers, Ph.D

Charles River Laboratories, England, United Kingdom

Mark obtained his BSc. Hons. in chemistry at the University of Bath, before moving to the University of Oxford to undertake his PhD in natural product synthesis, under the supervision of Professor Jim Thomas.
He then joined Merck at its Neuroscience Research Centre, leading cross-functional teams for CNS disorders. At Merck, Mark’s team identified the GABAA α5 inverse agonist MRK-016 that progressed to clinical evaluation for the treatment of cognitive deficit.
Mark subsequently joined BioFocus, since acquired by Charles River Laboratories (CRL). At CRL he is a Science Director with responsibility for integrated projects, working across a range of therapeutic areas and target families. Mark is an author of 36 peer-reviewed scientific publications and a named inventor on >70 patents.

Disclosure information not submitted.

Presentation(s):

• Discovery: Innovation at Every Turn

  Monday, February 5, 2024
  12:00 PM – 1:00 PM EST